News

Hanmi Pharmaceutical also will be making a strategic investment in Allegro that will advance and accelerate the global development program for Luminate. Under the terms of the agreements,

Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the US. The Company will be a leader in Oncology, with nearly

"This new patent allowance is representative of our intellectual property strategy aimed at protecting and enhancing the value of VAL-083," stated Jeffrey Bacha, DelMar’s president and CEO. "This

As life expectancy rises worldwide, Alzheimer’s is becoming an increasingly lethal disease, placing enormous strain on caregivers and healthcare systems. With over 500,000 patients in Canada alone, the

The ongoing multi-center, open label dose escalation BP-004 trial is being held at leading transplant centers in Europe and in the US. Phase I arm of the trial

The deal, facilitated by the Johnson & Johnson Innovation Center, will see Janssen develop and may commercialize the pharmaceutical candidate in inflammatory bowel disease (IBD). As part of

As part of the deal, the research capabilities of the two parties will be brought together to identify new immune-modulatory agents for oncology, autoimmune and respiratory disorders. In

The deal will see evaluation of the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials. As part

Enadenotucirev (previously called as ColoAd1) is currently being evaluated in a Phase I/II trial (OCTAVE) in platinum-resistant ovarian cancer patients across multiple UK cancer centres. The Phase I/II